Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. (Nasdaq: SSII) filed a Form 8-K dated 15 July 2025 to disclose an operational milestone. The company reports that it has now installed more than 100 SSi Mantra surgical robotic systems across India and six other countries. Collectively, the installed base has facilitated over 5,000 surgical procedures, including 240 cardiac surgeries and 32 telesurgeries.
The filing contains no revenue, earnings, guidance or transactional information; it simply furnishes the related press release as Exhibit 99.1. While financial details are absent, the figures provided highlight growing clinical adoption and an expanding geographic presence for the Mantra platform.
SS Innovations International, Inc. (SSII) filed an amended Form 4 for Director and COO-Americas Barry F. Cohen. The amendment corrects the total share count after three small open-market purchases:
- 100 shares at $8.75 on 04/17/2025
- 100 shares at $8.90 on 04/22/2025
- 226 shares at $9.00 on 04/22/2025
The transactions add 426 shares in total, bringing Cohen’s directly held position to 8,866,888 common shares. No derivative securities were involved. The filing states the prior Form 4 contained an inadvertent misstatement of holdings, which is now rectified. While the dollar value of the purchases is modest, insider buying—especially by a director/officer—can be interpreted as a signal of confidence. However, the tiny size relative to Cohen’s existing 8.87 million-share stake limits financial materiality.